Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I called Lifeline, the suicide help line. Got a freakin' call center in Pakistan . I told them I was suicidal. They all got all excited and asked if I could drive a truck.
Moses said to the children of Israel, "Pick up your shovels, mount your asses and camels, and I will lead you to the promised land". Then about 75 years ago, Roosevelt said, "Lay down your shovels, sit on your asses, and light up a Camel, this is the promised land". Now Obama has stolen your shovel, taxed your asses, raised the price of Camels and bankrupted the promised land.
I've own DCTH for years had about 20k shares from around .50 or so, over the years I have sold most for around 3-7.00. Still have 2k though, oh well
I got 10k at .09 filled in one order today
CAMH news.
Cambridge Heart Receives FDA 510(k) Clearance for Its Microvolt T-Wave Alternans Module to Measure Risk for Sudden Cardiac Death
2:31p ET April 15, 2010 (Business Wire)
Cambridge Heart, Inc. (OTCBB: CAMH), today announced that it has received clearance from the U.S. Food and Drug Administration to begin marketing its Microvolt T-Wave Alternans (MTWA) OEM module. The MTWA OEM module is designed to work with existing cardiac stress test platforms distributed by other manufacturers. This FDA 510(k) clearance allows Cambridge Heart to begin marketing the MTWA OEM module integrated with the Q-Stress line of stress systems manufactured by Cardiac Science Corporation, Inc. (NASDAQ:CSCX).
The non-invasive MTWA test measures small heartbeat irregularities that indicate a patient's heightened risk for sudden cardiac arrest.
In June 2009, Cambridge Heart and Cardiac Science entered into a five-year development and distribution partnership, whereby Cardiac Science will market the MTWA OEM module to its existing base of installed stress systems as an upgrade, and to new stress customers as an optional feature. Development of the MTWA OEM module was completed in early February 2010. Sales training and pre-launch activities will take place between now and an expected launch date later this year.
"The development of MTWA as an add-on module for our stress systems allows us to bring new technology to our customers and extend our leadership in the stress segment," said Dave Marver, Cardiac Science President & CEO. "This initiative is consistent with our goal to help our physician customers by offering simple, cost-effective, and efficient devices that improve public health."
Ali Haghighi-Mood, Cambridge Heart's President and CEO said, "We are pleased to have reached this important milestone in a relatively short period of time. Obtaining the FDA clearance is a big step as we implement our new business model that aims to market the MTWA technology via partnerships with the leading stress test manufacturers. Most immediately, the clearance allows us to focus our activities on working with Cardiac Science, training its sales force and distributors and engaging in other activities in advance of the product launch."
About Cambridge Heart, Inc.
Cambridge Heart develops and commercializes non-invasive diagnostic tests for cardiac disease, with a focus on identifying those at risk for sudden cardiac arrest (SCA). The Company's products incorporate proprietary Microvolt T-Wave Alternans(TM) measurement technologies, including the patented Analytic Spectral Method(R) and ultrasensitive disposable electrode sensors. The Company's MTWA test, originally based on research conducted at the Massachusetts Institute of Technology, is reimbursed by Medicare under its National Coverage Policy.
Cambridge Heart, founded in 1990, is based in Tewksbury, MA. It is traded on the Over-The-Counter Bulletin Board (OTCBB) under the symbol CAMH.OB.
http://www.cambridgeheart.com.
Statements contained in this press release that are not purely historical are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. In some cases, we use words such as "believes", "expects", "anticipates", "plans", "estimates", "could", and similar expressions that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements about the Company's expected launch of the MTWA Module, the Company's expected reductions in operating expenses, and the Company's belief that existing resources and currently projected financial results are sufficient to fund operations through December 31, 2010. Actual results may differ materially from those indicated by these forward-looking statements. Material deviations from our current operating plan, including a delay in gaining FDA clearance for the MTWA Module, a delay in launching the MTWA Module with Cardiac Science, lower than expected sales to Cardiac Science, lower than expected sales of our Heartwave II System, may cause or contribute to such differences. Other factors that may cause or contribute to such differences include failure to achieve broad market acceptance of the Company's MTWA technology, failure of our sales and marketing organization to market our products effectively, inability to hire and retain qualified clinical applications specialists in the Company's target markets, failure to obtain or maintain adequate levels of first-party reimbursement for use of the Company's MTWA test, customer delays in making final buying decisions, decreased demand for the Company's products, failure to obtain funding necessary to develop or enhance our technology, adverse results in future clinical studies of our technology, failure to obtain or maintain patent protection for our technology and other factors identified in our most recent Annual Report on Form 10-K under "Risk Factors", which is on file with the SEC and available at www.EDGAR.com. In addition, any forward-looking statements represent our estimates only as of today and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so except as may be legally necessary, even if our estimates should change.
SOURCE: Cambridge Heart, Inc.
At Cambridge Heart:
Vincenzo LiCausi, 978-654-7600 x 6645
Chief Financial Officer
vincenzol@cambridgeheart.com
or
Media:
KOGS Communication
Edna Kaplan, 781-639-1910
kaplan@kogspr.com
or
Investor Relations:
Allen & Caron
Matt H. Clawson, 949-474-4300
matt@allencaron.com
NWBO has moved nicely the last two days.
http://www.investmentu.com/IUEL/2009/November/dendreon-corp.html
your thoughts on IXSBF
2:39 PM ET 3/23/10 | BusinessWire
InNexus Biotechnology Inc. (TSX:IXS.V) (http://www.ixsbio.com), commercializing the next generation of antibodies based on its groundbreaking Dynamic Cross Linking (DXL(TM)) technology, today announces the Journal of Anti-Cancer Drugs is publishing the manuscript titled, "The autophilic anti-CD20 antibody DXL625 displays enhanced potency due to lipid raft-dependent induction of apoptosis" by Bingaman et al.
The manuscript showcases in detail how InNexus' lead product, DXL625 (anti-CD20) induces apoptosis (cell death) in cancer cells, having a mechanism not previously seen with commercially available antibody drugs including Rituxan(R). Comparison experiments were also conducted with Rituxan(R) to confirm this unique cell killing ability.
"DXL625 was found to be superior in (1) inhibiting growth of lymphoma cells and (2) directly inducing lymphoma cell death," said Dr. Thomas Kindt, InNexus' Chief Scientific Officer. "Treatment with DXL625, even in the absence of any secondary immune mechanisms, elicited significant levels of lymphoma cell apoptosis, while equivalent treatment with the commercially available alternative did not."
"Our manuscript provides wonderful insight into our DXL(TM) technology and is indeed a testament to the accomplishments of our scientific team and the value of their work toward the advancement of cancer research," said Jeff Morhet, Chief Executive Officer of InNexus. "We look forward to advancing DXL625 to Phase I clinical trials and look forward to the team's continued success through 2010 and beyond."
The manuscript is available now for download in the Published Ahead of Print section of the Journal's website.
About the Journal of Anti-Cancer Drugs
Anti-Cancer Drugs (on the web at http://journals.lww.com/anti-cancerdrugs) reports both clinical and experimental results related to anti-cancer drugs, and welcomes contributions on anti-cancer drug design, drug delivery, pharmacology, hormonal and biological modalities and chemotherapy evaluation. An internationally refereed journal devoted to the fast publication of innovative investigations on therapeutic agents against cancer, Anti-Cancer Drugs aims to stimulate and report research on both toxic and non-toxic anti-cancer agents. Consequently, the scope on the journal will cover both conventional cytotoxic chemotherapy and hormonal or biological response modalities such as interleukins and immunotherapy.
I went to a new deli store on a monday, the subs were like 3-4 bucks(it was 20 years ago) the meat was like 3-4 inches high.
By wednesday there was like 20 people in line, by friday about 50.
On Sat. I went again and the meat was like 1-2 inches high. I said hey what gives, they said 'oh we thought there was 24 oz in a pound'
PPRG.OB HIMSS predicts $14.4 Billion in Hospital IT Spending over next 5 years
June 17, 2009
A healthcare industry association projects that hospitals will spend more than $14 billion on information technology systems during the next five years, but it said capital outlays will remain relatively flat until stimulus-related funding kicks in.
The Healthcare Information and Management Systems Society (HIMSS) discussed hospital spending trends June 16, based on the group’s tracking of more than 5,000 U.S. hospitals. HIMSS pegged hospital outlays, impacted by the American Recovery and Reinvestment Act, at $14.4 billion through 2014. Expenditures on systems such as electronic medical records, computerized practitioner order entry and clinical decision support is expected to hit $1.7 billion this year.
Mike Davis, executive vice president of HIMSS Analytics, suggested hospitals face a constrained funding environment in the near term. He said banks are still not lending to the hospitals he’s encountered, including those that have submitted business plans based on ARRA. In addition, hospital endowment funds, a source of funding for capital acquisitions, have lost 20 percent to 30 percent of their value in some cases, he said.
For the rest of this article please see the govhealthit.com website here.
Tagged as: HIMSS
Read more: http://emrdailynews.com/2009/06/17/himss-predicts-14-4-billion-in-hospital-it-spending-over-next-5-years/#ixzz0hllbW5KM
====================
WHAT PPRG DOES--->>>
Patient Portal Technologies, Inc., through its operating subsidiaries Patient Portal Connect, Inc. (PPC) and TB&A Hospital Television, Inc. (TB&A), provides patient centric nonmedical services, which improves hospital financial performance. The Company’s products and services are delivered over the Company’s technology platform. The platform is used by the Company as the delivery system for its services. The Company uses the technology to create a communication portal that allows the third parties to communicate and exchange information. The products and services of the Company include HealthCast Patient Network System (HealthCast), MedEx Home Delivery (MedEx), Instant Response Line and Quick Pulse Surveys. In March 2007, the Company completed the acquisition of 9% interest in Omnicast, Inc
================
RECENT EVENTS---->
Patient Portal Technologies Inc: Key Developments
View:
Patient Portal Technologies, Inc. Finalizes Sale of Equipment Business Unit
January 12, 2010
Patient Portal Technologies, Inc. announced that it closed on January 8, the sale of its hospital equipment business unit to a former executive of the Company, Tom Brunskole, for $820,000. The transaction included the sale of the name TB&A as well as certain inventory and hospital equipment purchase contracts. The sale price included cash as well as the assumption of certain debt and obligations of the Company. As part of the transaction both companies will continue to share space and facilities in Amherst New York. Patient Portal also executed a joint marketing services agreement which will allow the Company to continue to provide hospital television equipment to its customers under favorable market terms and it is retaining its technical support capabilities.
Patient Portal Technologies, Inc. Announces Award Of Five Year Contract Extension With Crozer Chester Medical Center
January 8, 2010
Patient Portal Technologies, Inc. announced that it has been awarded a contract extension from Crozer-Chester Medical Center to provide its Total Satisfaction Service Program including bedside education and entertainment systems, patient bedside communications systems, and related patient support services. Part of the five-hospital Crozer-Keystone Health System, Crozer-Chester Medical Center (Crozer) is a 371-bed not-for-profit tertiary care teaching hospital.
Patient Portal Technologies, Inc. Announces Award Of Five Year Contract Extension With Delaware County Memorial Hospital
January 7, 2010
Patient Portal Technologies, Inc. announced that it has been awarded a contract extension from Delaware County Memorial Hospital to provide its Total Satisfaction Service Program, including bedside education and entertainment services, patient bedside communications systems, and related patient support services.
Patient Portal Technologies, Inc. Announces New Multi Year Contract With Taylor Hospital
November 17, 2009
Patient Portal Technologies, Inc. announced that it has been awarded a five-year, million dollar plus contract from Crozer-Chester Medical Center, on behalf of its Taylor Hospital division, to provide a full range of its patient satisfaction services. Included in the service offering is management of the television and phone system, providing HealthCast, the bedside patient education platform and Instant Response, a patient response tool for non medical support.
Patient Portal Technologies, Inc. Comments On Q4 2009 and FY 2010 Earnings Guidance
November 3, 2009
Patient Portal Technologies, Inc. announced that it for the fourth quarter of 2009, it anticipates profit to continue to grow throughout the fourth quarter of 2009 and into fiscal 2010.
==============
RECENT 8-K--->>>
Form 8-K for PATIENT PORTAL TECHNOLOGIES, INC.
________________________________________
12-Jan-2010
Other Events, Financial Statements and Exhibits
Item 8.01 Other Events. On January 8, 2010, the Company closed on the sale of
its hospital television equipment business to a former executive for $820,000. The consideration consisted of cash and the assumption of certain Company liabilities.
The transaction included the sale of the name TB&A as well as certain inventory and hospital equipment purchase contracts. The sale is expected to have an ongoing favorable impact on the Company's future operating profits.
=======================
From 3rd qtr release-
OVERALL
Business activity and acceptance of new products, HealthCast, Quick Pulse Surveys and our other information based services continues to be strong into the fourth quarter. Sales from equipment are also trending stronger than the first six months of the year. The Company continues to improve its internal business processes utilizing its technology and anticipates profit to continue to grow throughout the remainder of 2009 and into 2010. Company CEO, Kevin Kelly, commented, "We are pleased with the demand for our new patient based services as well as the continued improvements being made in our internal operating systems." He added, "Our unique approach to delivering and servicing our customers' needs is resulting in a building demand for our services. We believe that growth in service revenue and profits will continue into 2010 and we continue to be confident in our ability to gain market share in this area."
Patient Portal Technologies, Inc. assists hospitals in increasing financial performance by providing services that improve and enhance the patients experience before, during and after their hospital stay. The company provides its products and solutions to hospitals and healthcare facilities throughout the entire United States
To view the website and obtain Company information go to http://www.patientportal.com.
======================
From their www site-
Patient Portal Advantage
We’ve developed the first interactive support platform with instant delivery of information, products, and services.
Our services enhance what hospitals do for patients in a full continuum of care.
We fulfill all service and product needs before, during, and after a hospital stay.
We have targeted access to millions of patient and their families.
Competitive Advantage
The key-competitive advantage of the Patent Portal platform is that it requires minimal capital, can integrate with legacy systems, has a low per patient cost, and can be installed with minimal physical modification to the facilities. These factors eliminate all of the barriers to adoption that healthcare facilities typically face.
Essentially, our timing is perfect. Since rolling out this solution in late 2007, every presentation has resulted in either a signed contract or a request for proposal with an indication of moving forward with the relationship.
By focusing solely on the healthcare market, Patient Portal has built a delivery platform that is flexible enough to add new services as the market demands and customized enough to make sense to healthcare facilities challenged with discerning the best use of every dollar for maximum impact in a competitive market.
Monday announcement, I like that. Could be good news. Unlike Friday after 4pm announcements.
My Favorite country song is
If I shot her when I wanted to, I would be out of prison by now.
Minnesotans For Global Warming’ Call Out Gore Over Harsh Winter in ‘Frozen Wasteland’
http://www.breitbart.tv/minnesotans-for-global-warming-call-out-gore-over-harsh-winter-in-frozen-wasteland/
To the tune of "Teenage Wasteland": "Al Gore is liar. His pants are on fire. Plus, he's getting rich off carbon offsets."
Like any corrupt Chicago politician, Obama would frequently go the cemetery to register voters. One night he came across a grave so old and worn that he couldn't make out the name on the tombstone. The staffer holding the flashlight got impatient and suggested that they just move on to the next plot. Obama angrily exclaimed, "This person has as much right to vote as anyone else here!"
Obama's Home Teleprompter Malfunctions During Family Dinner
When asked if he would join Palin in Tahiti Obama replied, "No I must go to Haiti, our 57th state."
I wouldn't trust the whitehouse with my money. I'd do the red cross. Rahm the fish might skim some off the top
Did anyone hear this ?
former prime minister of Haiti yesterday say that all money sent to Haiti will be ripped off by the government?
Every nickle.
land of Duke, Wake Forest, Davidson etc
CTEI have you looked into it ?
"-FDA approved homeopathic therapy for Chronic Pain "
does the FDA rule on homeopathic therapys
because of their long use in the United States, the U.S. Congress passed a law in 1938 declaring that homeopathic remedies are to be regulated by the FDA in the same manner as nonprescription, over-the-counter (OTC) drugs, which means that they can be purchased without a physician's prescription. Today, although conventional prescription drugs and new OTC drugs must undergo thorough testing and review by the FDA for safety and effectiveness before they can be sold, this requirement does not apply to homeopathic remedies.
Remedies are required to meet certain legal standards for strength, quality, purity, and packaging. In 1988, the FDA required that all homeopathic remedies list the indications for their use (i.e., the medical problems to be treated) on the label. The FDA also requires the label to list ingredients, dilutions, and instructions for safe use.
thoughts on MSBT, they also have a blood filter systems
I've been holding since .14. I'll wait longer
Man my CRPP looks good.
CRPP is steaming
Brig, I own CRPP
EZEN, up. with good news.
NMXS is a thing of beauty.
eye on, every time Pedro points to his head , is he telling the yankees he wants to give some?
After last night the red soxs lost the support of the nation, talk about the curse of the Bambino. I thought I could never say this,...Go Yankees.
anyone still own NMXS, nice move
Does Howard's Pub still stand? Anyone know?
NSDM is a diamond in the rough.
Wise, I think so, my wife likes Diamonds
Wise, NSDM, ok I'm in for 10000 shs.
CYTP, watch it, it's gonna (insert pump word here).
I'm playing with my CRPP
CYTP is UP .0003
CYTP .0028 will this be the next runner